Position in LYEL
as of Mar 31, 2026
· filed May 6, 2026
Position Value
$800,714
New position
Shares Held
39,916
first reported quarter
Ownership
0.171%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Clearstead Advisors, LLC holds $49,363,406 across 77 Biotechnology names. LYEL ranks #11 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNLI |
Denali Therapeutics Inc.
|
737,990 | $14,169,408 | |
| 2 | VIR |
Vir Biotechnology, Inc.
|
1,216,400 | $10,898,944 | |
| 3 | NAUT |
Nautilus Biotechnology, Inc.
|
2,329,784 | $9,039,561 | |
| 4 | BEAM |
Beam Therapeutics Inc.
|
121,230 | $2,888,910 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
345,700 | $2,651,519 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,427 | $1,530,292 | |
| 7 | SRRK |
Scholar Rock Holding Corp
|
26,074 | $1,281,797 | |
| 8 | SANA |
Sana Biotechnology, Inc.
|
336,781 | $969,929 |
All Filings in LYEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $800,714 | 39,916 | Shares | Sole | 2026-05-06 | |
| No filing history on record for this holder in this stock. | ||||||